Literature DB >> 21846474

Phenylalanine 93 of the human UGT1A10 plays a major role in the interactions of the enzyme with estrogens.

Camilla Höglund1, Nina Sneitz, Anna Radominska-Pandya, Liisa Laakonen, Moshe Finel.   

Abstract

Little is currently known about the substrate binding site of the human UDP-glucuronosyltransferases (UGTs) and the structural elements that affect their complex substrate selectivity. In order to further understand and extend our earlier findings with phenylalanines 90 and 93 of UGT1A10, we have replaced each of them with Gly, Ala, Val, Leu, Ile or Tyr, and tested the activity of the resulting 12 mutants toward eight different substrates. Apart from scopoletin glucuronidation, the F90 mutants other than F90L were nearly inactive, while the F93 mutants' activity was strongly substrate dependent. Hence, F93L displayed high entacapone and 1-naphthol glucuronidation rates, whereas F93G, which was nearly inactive in entacapone glucuronidation, was highly active toward estradiol, estriol and even ethinylestradiol, a synthetic estrogen that is a poor substrate for the wild-type UGT1A10. Kinetic analyses of 4-nitrophenol, estradiol and ethinylestradiol glucuronidation by the mutants that catalyzed the respective reactions at considerable rates, revealed increased K(m) values for 4-nitrophenol and estradiol in all the mutants, whilst the K(m) values of F93G and F93A for ethinylestradiol were lower than in control UGT1A10. Based on the activity results and a new molecular model of UGT1A10, it is suggested that both F90 and F93 are located in a surface helix at the far end of the substrate binding site. Nevertheless, only F93 directly affects the selectivity of UGT1A10 toward large and rigid estrogens, particularly those with substitutions at the D ring. The effects of F93 mutations on the glucuronidation of smaller or less rigid substrates are indirect, however.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21846474      PMCID: PMC3188330          DOI: 10.1016/j.steroids.2011.07.017

Source DB:  PubMed          Journal:  Steroids        ISSN: 0039-128X            Impact factor:   2.668


  30 in total

1.  High-performance liquid chromatographic method combining radiochemical and ultraviolet detection for determination of low activities of uridine 5'-diphosphate-glucuronosyltransferase.

Authors:  S Kaivosaari; J S Salonen; J Mortensen; J Taskinen
Journal:  Anal Biochem       Date:  2001-05-15       Impact factor: 3.365

2.  Effects of cell differentiation and assay conditions on the UDP-glucuronosyltransferase activity in Caco-2 cells.

Authors:  Hongbo Zhang; Ari Tolonen; Timo Rousu; Jouni Hirvonen; Moshe Finel
Journal:  Drug Metab Dispos       Date:  2010-11-23       Impact factor: 3.922

Review 3.  Substrate specificity of plant UDP-dependent glycosyltransferases predicted from crystal structures and homology modeling.

Authors:  Sarah A Osmani; Søren Bak; Birger Lindberg Møller
Journal:  Phytochemistry       Date:  2009-02-13       Impact factor: 4.072

4.  A molecular model of the human UDP-glucuronosyltransferase 1A1, its membrane orientation, and the interactions between different parts of the enzyme.

Authors:  Liisa Laakkonen; Moshe Finel
Journal:  Mol Pharmacol       Date:  2010-03-09       Impact factor: 4.436

5.  The specificity of glucuronidation of entacapone and tolcapone by recombinant human UDP-glucuronosyltransferases.

Authors:  P Lautala; B T Ethell; J Taskinen; B Burchell
Journal:  Drug Metab Dispos       Date:  2000-11       Impact factor: 3.922

6.  How many and which amino acids are responsible for the large activity differences between the highly homologous UDP-glucuronosyltransferases (UGT) 1A9 and UGT1A10?

Authors:  Katriina Itäaho; Liisa Laakkonen; Moshe Finel
Journal:  Drug Metab Dispos       Date:  2010-01-20       Impact factor: 3.922

7.  Determination of mRNA expression of human UDP-glucuronosyltransferases and application for localization in various human tissues by real-time reverse transcriptase-polymerase chain reaction.

Authors:  Shuji Ohno; Shizuo Nakajin
Journal:  Drug Metab Dispos       Date:  2008-10-06       Impact factor: 3.922

8.  Dopamine is a low-affinity and high-specificity substrate for the human UDP-glucuronosyltransferase 1A10.

Authors:  Katriina Itäaho; Michael H Court; Päivi Uutela; Risto Kostiainen; Anna Radominska-Pandya; Moshe Finel
Journal:  Drug Metab Dispos       Date:  2008-12-30       Impact factor: 3.922

9.  The configuration of the 17-hydroxy group variably influences the glucuronidation of beta-estradiol and epiestradiol by human UDP-glucuronosyltransferases.

Authors:  Katriina Itäaho; Peter I Mackenzie; Shin-ichi Ikushiro; John O Miners; Moshe Finel
Journal:  Drug Metab Dispos       Date:  2008-08-21       Impact factor: 3.922

10.  Effect of the beta-glucuronidase inhibitor saccharolactone on glucuronidation by human tissue microsomes and recombinant UDP-glucuronosyltransferases.

Authors:  Lauren Oleson; Michael H Court
Journal:  J Pharm Pharmacol       Date:  2008-09       Impact factor: 3.765

View more
  3 in total

1.  Role of human UDP-glucuronosyltransferases in the biotransformation of the triazoloacridinone and imidazoacridinone antitumor agents C-1305 and C-1311: highly selective substrates for UGT1A10.

Authors:  Barbara Fedejko-Kap; Stacie M Bratton; Moshe Finel; Anna Radominska-Pandya; Zofia Mazerska
Journal:  Drug Metab Dispos       Date:  2012-06-01       Impact factor: 3.922

2.  Mutational analysis of the integral membrane methyltransferase isoprenylcysteine carboxyl methyltransferase (ICMT) reveals potential substrate binding sites.

Authors:  Melinda M Diver; Stephen B Long
Journal:  J Biol Chem       Date:  2014-07-24       Impact factor: 5.157

3.  Molecular Docking-Based Design and Development of a Highly Selective Probe Substrate for UDP-glucuronosyltransferase 1A10.

Authors:  Risto O Juvonen; Sanna Rauhamäki; Sami Kortet; Sanna Niinivehmas; Johanna Troberg; Aleksanteri Petsalo; Juhani Huuskonen; Hannu Raunio; Moshe Finel; Olli T Pentikäinen
Journal:  Mol Pharm       Date:  2018-02-15       Impact factor: 4.939

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.